<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751448</url>
  </required_header>
  <id_info>
    <org_study_id>017-342</org_study_id>
    <nct_id>NCT04751448</nct_id>
  </id_info>
  <brief_title>COLON-MD: Colon Cancer Longitudinal Study</brief_title>
  <acronym>COLON-MD</acronym>
  <official_title>COLON MD: Colon Cancer Longitudinal Study of the Microbial Metabolites and Dietary Factors That Influence Response to Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this proposal is to identify how the composition of the gut microbiome and diet&#xD;
      interact to impact chemotherapy-induced diarrhea incidence and severity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this longitudinal observational study patients will supply samples of their gut microbiome&#xD;
      prior to scheduled colonoscopy or surgery along with dietary intake and blood samples; the&#xD;
      relative abundance of microbes from those samples along with dietary data will be used to&#xD;
      predict the presence or absence and severity of chemotherapy-induced diarrhea. Microbiome and&#xD;
      diet based predictions from blinded samples will be combined to map the diet-microbiome&#xD;
      changes during treatment to the changes in immune markers and risk of chemotherapy-induced&#xD;
      diarrhea.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiome-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer</measure>
    <time_frame>3 years</time_frame>
    <description>Microbiome analysis from at least 112 blinded samples will be conducted from fecal samples to determine sensitivity, specificity and accuracy (reported as %) of a microbiome-based predictor of chemotherapy-induced diarrhea in stage II/III colon cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer</measure>
    <time_frame>3 years</time_frame>
    <description>Dietary analysis from at least 112 blinded surveys will be conducted using food frequency questionnaires (DHQ-III) plus 24 hour recalls collected during treatment to determine sensitivity, specificity and accuracy (reported as %) of a dietary-based predictor of chemotherapy-induced diarrhea in stage II/III colon cancer.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>All patients going on study will be put in the observational grouping for blood and tissue collection with option for stool collection.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool sample kit, Tissue at time of surgery, blood draw(2 vials) at specific times up to 5&#xD;
      times.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stage II/III colon cancer patient, prior to surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage II/III colon cancer diagnosis&#xD;
&#xD;
          -  Age &gt;18 and &lt; or equal to 79.&#xD;
&#xD;
          -  Ability to perform informed consent&#xD;
&#xD;
          -  FOLFOX treatment expected&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not diagnosed with Stage II/III colon cancer.&#xD;
&#xD;
          -  Not Pregnant&#xD;
&#xD;
          -  Does not have Lynch syndrome or FAP diagnosis.&#xD;
&#xD;
          -  Inability to perform inform consent&#xD;
&#xD;
          -  inability to comply with follow up program&#xD;
&#xD;
          -  history of prior colon cancer diagnosis&#xD;
&#xD;
          -  previous treatment with antibiotics in the last month.&#xD;
&#xD;
          -  previous bowel resection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Ainslie</last_name>
      <phone>254-724-3796</phone>
      <email>melissa.ainslie@bswhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Karen Templeton</last_name>
      <phone>254-724-1377</phone>
      <email>karen.templeton@bswhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Lucas Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hitesh Singh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage II</keyword>
  <keyword>Stage III</keyword>
  <keyword>FOLFOX Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT04751448/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

